EMORI Makoto

写真a

Affiliation

School of Medicine, Department of Orthopaedic Surgery

Job title

Associate Professor
To the head of this page.▲

Research Areas 【 display / non-display 】

  • Life sciences   Orthopedics  

To the head of this page.▲

Affiliation 【 display / non-display 】

  • Sapporo Medical University   Department of Orthopaedic Surgery  

To the head of this page.▲
 

Papers 【 display / non-display 】

  • Establishment and characterization of the novel myxofibrosarcoma cell line, SMU-MFS

    Naoya Nakahashi, Makoto Emori, Kohichi Takada, Yasutaka Murahashi, Junya Shimizu, Kazuyuki Murase, Tomohide Tsukahara, Shintaro Sugita, Akira Takasawa, Kousuke Iba, Atsushi Teramoto, Makoto Osanai

    Human Cell ( Springer Science and Business Media LLC )  38 ( 1 )  2024.12

    DOI

  • Secondary Osteosarcoma After Carbon‐Ion Radiotherapy for Desmoid‐Type Fibromatosis: A Case Report

    Mizuki Aketo, Makoto Emori, Kohichi Takada, Kazuyuki Murase, Yohei Arihara, Junya Shimizu, Yasutaka Murahashi, Masahiko Okamoto, Shintaro Sugita, Atsushi Teramoto

    Cancer Reports ( Wiley )  7 ( 11 )  2024.11

    　View Summary

    ABSTRACT Background Radiotherapy is considered an alternative treatment for unresectable or pharmacologically resistant desmoid‐type fibromatosis. While it results in relatively good local control, the risk of secondary malignancy remains a concern. Case We present a case of secondary osteosarcoma after carbon‐ion radiation therapy (CIRT). A 31‐year‐old male patient presented with left thigh pain. The tumor was located between the left gluteus maximus and gluteus medius and extended to the vastus lateralis and biceps femoris. It was diagnosed as desmoid‐type fibromatosis after needle biopsy. The patient was treated with several medications, including a cyclooxygenase 2 inhibitor and tamoxifen; however, his left thigh pain did not improve. He was treated with CIRT 1 year after diagnosis (67.2 Gy [relative biological effectiveness] 16fr/4wks). He developed osteosarcoma of the left femur 8 years later. He underwent chemotherapy and tumor excision with disarticulation of the left hip. Pulmonary metastasis was detected 6 and 17 months after the definitive surgery and excised using metastasectomy. However, he died due to the recurrence of multiple pulmonary metastases 29 months after the definitive surgery. Conclusions In this case, we believe that the low radiation dose to the femur may have caused secondary malignancy.

    DOI

  • LMNA::NTRK1 Fusion-positive Leiomyosarcoma: Discrepancy between DNA-based Comprehensive Genomic Profiling and RNA Sequencing.

    Norito Suzuki, Masashi Idogawa, Makoto Emori, Kazuyuki Murase, Yohei Arihara, Hajime Nakamura, Makoto Usami, Tomohiro Kubo, Ichiro Kinoshita, Shintaro Sugita, Takashi Tokino, Tadashi Hasegawa, Akihiro Sakurai, Kohichi Takada

    Internal medicine (Tokyo, Japan)   63 ( 15 ) 2215 - 2219  2024.08  [Domestic journal]

    　View Summary

    A 26-year-old man presented with a tumor in the left soleus muscle. The tumor was diagnosed as a locally advanced leiomyosarcoma. The patient was treated with irradiation followed by wide resection. One year after surgery, the patient presented with multiple lung metastases. Despite aggressive sequential chemotherapy, systemic metastatic tumors continued to develop. To explore therapeutic options for the patient, we performed DNA-based CGP with FoundationOne® CDx (F1). F1 identified an out-of-strand rearrangement of the NOS1AP::NTRK1 gene, which has not been previously reported. In contrast, RNA sequencing revealed an in-frame LMNA::NTRK1 gene, which is an oncogenic fusion gene.

    DOI PubMed

  • Crizotinib therapy for congenital embryonal rhabdomyosarcoma associated with an <i>ATIC–ALK</i> gene fusion

    Yusuke Akane, Masaki Yamamoto, Akira Takebayashi, Ryo Hamada, Keita Igarashi, Makoto Emori, Shintaro Sugita, Kohichi Takada, Tadashi Hasegawa, Takeshi Tsugawa

    Pediatric Blood &amp; Cancer ( Wiley )   2024.06

    DOI

  • Development of T cell receptor-engineered T cells targeting the sarcoma-associated antigen papillomavirus binding factor.

    Shuto Hamada, Tomohide Tsukahara, Yuto Watanabe, Kenji Murata, Yuka Mizue, Terufumi Kubo, Takayuki Kanaseki, Yoshihiko Hirohashi, Makoto Emori, Munehide Nakatsugawa, Atsushi Teramoto, Toshihiko Yamashita, Toshihiko Torigoe

    Cancer science   115 ( 1 ) 24 - 35  2024.01  [International journal]

    　View Summary

    We previously identified papillomavirus binding factor (PBF) as an osteosarcoma antigen recognized by an autologous cytotoxic T lymphocyte clone. Vaccination with PBF-derived peptide presented by HLA-A24 (PBF peptide) elicited strong immune responses. In the present study, we generated T cell receptor-engineered T cells (TCR-T cells) directed against the PBF peptide (PBF TCR-T cells). PBF TCR was successfully transduced into T cells and detected using HLA-A*24:02/PBF peptide tetramer. PBF TCR-T cells generated from a healthy donor were highly expanded and recognized T2-A24 cells pulsed with PBF peptide, HLA-A24+ 293T cells transfected with PBF cDNA, and sarcoma cell lines. To establish an adoptive cell therapy model, we modified the PBF TCR by replacing both α and β constant regions with those of mice (hybrid PBF TCR). Hybrid PBF TCR-T cells also showed reactivity against T2-A24 cells pulsed with PBF peptide and to HLA-A24+ 293T cells transfected with various lengths of PBF cDNA including the PBF peptide sequence. Subsequently, we generated target cell lines highly expressing PBF (MFH03-PBF [short] epitope [+]) containing PBF peptide with in vivo tumorigenicity. Hybrid PBF TCR-T cells exhibited antitumor effects compared with mock T cells in NSG mice xenografted with MFH03-PBF (short) epitope (+) cells. CD45+ T cells significantly infiltrated xenografted tumors only in the hybrid PBF TCR T cell group and most of these cells were CD8-positive. CD8+ T cells also showed Ki-67 expression and surrounded the CD8-negative tumor cells expressing Ki-67. These findings suggest that PBF TCR-T cell therapy might be a candidate immunotherapy for sarcoma highly expressing PBF.

    DOI PubMed

display all >>

To the head of this page.▲

Misc 【 display / non-display 】

To the head of this page.▲

Research Projects 【 display / non-display 】

  • Establishment of new treatment method for dedifferentiated chondrosarcoma

    Grant-in-Aid for Scientific Research (C)

    Project Year :

    2024.04
    -
    2027.03
     

    清水 淳也, 高澤 啓, 江森 誠人, 房川 祐頼, 佐藤 達也, 高田 弘一, 中橋 尚也

  • プロテオーム解析による骨肉腫の肺転移機序解明と新規治療開発

    基盤研究(C)

    Project Year :

    2023.04
    -
    2026.03
     

    江森 誠人, 高澤 啓, 高田 弘一, 中橋 尚也

  • ショットガンプロテオミクスを用いた神経線維腫の悪性化機序解明と治療への応用

    基盤研究(C)

    Project Year :

    2020.04
    -
    2023.03
     

    江森 誠人, 高澤 啓, 高田 弘一, 村橋 靖崇

    　View Summary

    神経線維腫1型患者で悪性末梢神経鞘腫瘍（MPNST）を3回外科的に切除したFFPE組織から、神経線維腫とMPNSTのレーザーマイクロダイセクションにより腫瘍切片を切り出し、タンパク質を抽出した。これら3病変に共通でMPNSTに有意に増加していたタンパク質は321種、神経線維腫に有意に増加していたタンパク質は18種であった。増加したタンパク質群のKEGG pathway解析で、MPNSTではタンパク質合成・プロセッシング・分解過程の全てが活性化され、特にプロテアソーム関連タンパクが多く増加(Fold Enrichment:7.93)していた。抗体入手が可能なプロテアソームサブユニット20S proteasome β2、PSMD2は免疫組織染色にてMPNSTで発現が亢進していた。このことからプロテアソーム選択的阻害剤がMPNSTに対する治療効果を示す可能性が示唆された。そこでMPNST細胞株sNF96.2,SCC94,SCC24で、プロテアソーム選択的阻害剤の暴露を行い、細胞株での増殖抑制を確認した。

  • Investigation of draggable fusion genes and diagnostic biomarker in bone and soft tissue sarcoma

    Grant-in-Aid for Scientific Research (C)

    Project Year :

    2018.04
    -
    2021.03
     

    Hamada Shuto

    　View Summary

    Fusion genes have been reported to occur in several bone and soft tissue sarcomas (BSTT). We tried to detect new draggable fusion genes to improve overall survival in BSTT. Especially, we analyzed fusion genes of epithelioid sarcoma. We identified nine candidates of fusion genes in a tumor sample of a 15 year-old Japanese patient, using next-generation sequences. Of them, GATSL2×GTF2I was confirmed to be a fusion.

  • Establishment of the testing targeted for CD109 antigen in soft tissue sarcoma

    Grant-in-Aid for Scientific Research (C)

    Project Year :

    2017.04
    -
    2020.03
     

    Emori Makoto

    　View Summary

    The purpose of this study is to establish the testing to detect early local recurrence or distant metastasis in soft tissue sarcomas. CD109 is a TGF-b co-receptor that regulates TGF-b receptor endocytosis and degrading. This relation may be associated with tumor proliferation, and immunohistochemical studies have demonstrated high level of expression in various cancers. We investigated the amount of CD109 antigen in serum in four patients who developed distant metastasis and compared the amount of CD109 between the preoperative and the distant metastasis phase. However, there were no significant change.

To the head of this page.▲